Educational Blogs

Why Anxiety Looks Different for Every Patient: A Clinical Perspective
Anxiety

Why Anxiety Looks Different for Every Patient: A Clinical Perspective

Anxiety is often described in broad terms, but in clinical settings it rarely looks the same from one patient to the next. Some people notice primarily physical sensations, while others experience ...

Read more
How Clinicians Evaluate Anxiety in Telehealth Settings
Anxiety

How Clinicians Evaluate Anxiety in Telehealth Settings

Many people experience worry, tension, or stress at different points in life. But when anxiety symptoms persist, change, or begin to interfere with daily functioning, a clinical evaluation may be a...

Read more
What to Expect During an Anxiety-Focused Telehealth Evaluation
Anxiety

What to Expect During an Anxiety-Focused Telehealth Evaluation

Considering a clinical evaluation for anxiety can raise practical questions—especially when that evaluation takes place through telehealth. Many patients wonder what a virtual visit involves, what ...

Read more
Cannabinoids and Anxiety: What the Science Says, and Why Clinical Guidance Matters.
Anxiety

Cannabinoids and Anxiety: What the Science Says, and Why Clinical Guidance Matters.

Anxiety disorders affect more than 40 million adults in the United States, making them one of the most common mental health challenges today. While traditional treatments such as therapy and prescr...

Read more
Important safety information

Prescription cannabinoid therapies require clinical oversight.

Common side effects

Prescription cannabinoid therapies may cause drowsiness, fatigue, changes in appetite, diarrhea, and dry mouth. Effects vary by patient, dose, and formulation.

Drug‑interaction risk

CBD can affect how the body metabolizes other medications through cytochrome P450 liver enzymes, which may alter the effectiveness or safety of prescriptions including blood thinners, anti‑seizure medications, and some antidepressants. Disclose all current medications and supplements to your clinician during evaluation.

Liver‑enzyme monitoring

Elevated liver enzymes have been observed in clinical research on CBD, particularly at higher doses. Your clinician may recommend liver‑function testing before or during your protocol. Patients with existing liver conditions require additional review.

Not FDA‑approved

Compounded cannabinoid formulations are prepared under FDA 503A regulations for individual patients. They are not FDA‑approved drugs and have not been evaluated by the FDA for safety, efficacy, or quality in the same way as commercial pharmaceuticals. Compounded medications are prescribed when a clinician determines a commercially available product is not appropriate for a specific patient.

This information is provided for educational purposes and does not replace clinical advice. Speak with a licensed clinician before beginning any cannabinoid protocol. Telehealth currently available in Colorado only. Individual results vary. Prescription decisions are made solely by a licensed clinician and are never automatic.